key: cord-0943060-fv435q74
authors: Xia, Tian; Wang, Yanfeng
title: Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome
date: 2020-05-13
journal: Am J Transplant
DOI: 10.1111/ajt.15992
sha: 87510f74b8ceb4964d3ab45ed65e231a51fee75c
doc_id: 943060
cord_uid: fv435q74

The ongoing outbreak of coronavirus disease 2019 (COVID‐19) first reported in Wuhan has been declared global public health emergency and a pandemic by the World Health Organization. Faced with this novel coronavirus, scientists have been trying to use drugs that have not been validated by rigorous clinical trials, such as lopinavir/ritonavir (LPV/r) and hydroxychloroquine (HCQ). These drugs may be used tentatively for general population with COVID‐19, but for solid organ transplant (SOT) recipients with long‐term immunosuppressive therapy and drug‐related metabolic diseases, antiviral drugs should be chosen with particular care. Notably, the elderly SOT patients commonly suffer from liver and kidney dysfunction of varying degrees, resulting in worse drug metabolism.

woman with COVID-19, whose tacrolimus trough level turned to be extremely high (90.5 ng/mL) after antiviral therapy with LPV/r, along with HCQ and ceftriaxone. We consider the combined therapeutic regimen of LPV/r and HCQ has an uncertain antiviral effect and even some potentially severe side effects in SOT recipients with COVID-19. Moreover, LPV/r and HCQ have a synergistic effect on tacrolimus, resulting in higher trough blood concentrations far beyond the expected range, which not only cause severe liver and kidney dysfunction and neurologic abnormalities, but also greatly damage the function of the immune system, leading to prolonged virus shedding, and multiple organ function failure, which is the leading cause of death in COVID-19 patients.

This article is protected by copyright. All rights reserved

No antiviral drug has yet been proven effective for the treatment of patients with COVID-19.

Protease inhibitors, including LPV/r, are known inhibitors of cytochrome P450 3A (CYP3A) and p-glycoprotein. However, tacrolimus is a substrate for CYP3A and p-glycoprotein 3 . The concentration of tacrolimus may increase and last for a long time after the introduction of LPV/r, even if LPV/r is discontinued promptly 4 . Additionally, HCQ and tacrolimus are the common substrates of CYP3A. Combination of immunosuppressants and LPV/r or HCQ is unfavorable for the disease improvement and protection of allograft due to over-immunosuppression, even resulting in severe cardiac toxicity due to their synergistic effect 5 . Furthermore, the therapeutic window of calcineurin inhibitors is very narrow and susceptible to a variety of drugs. When tacrolimus exceeds a certain concentration, the side effects are extremely harmful. Besides, the monitor of tacrolimus trough blood concentration was not fully available during the pandemic.

Hence, we do not recommend the simultaneous use of LPV/r and HCQ as an antiviral regimen in SOT recipients with COVID-19.

COVID-19 in solid organ transplant recipients: a single-center case series from Spain

Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)

This research was supported by the National Natural Science Foundation of China, Grant Nos.

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.